Rare Disease Report

Which Patients with Gaucher Disease Are Switching to the Oral Treatment Option?

JANUARY 01, 2015


Barry Rosenbloom, MD, Cedar Sinai Medical Center talks about the type of patients with Gaucher disease who are most likely to switch from intravenous enzyme replacement therapy to the new oral treatment option - Cerdelga (eliglustat).

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
$related$
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.